Loading…
Concentrating on High-Value Alzheimer’s Needs to Get to an End (CHANGE) Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Concentrating on High-value Alzheimer's Needs to Get to an End (CHANGE) Act of 2021 This bill modifies the requirements under Medicare for diagnosing and treating Alzheimer's disease and other cognitive impairments in older adults. Specifically, the bill expands the cognitive impairment detection benefit during annual wellness visits to require the use of validated detection tools and documentation of the results in the patient's medical record. Further, when a cognitive impairment is detected, the patient must be referred to an appropriate diagnostic service provider and other specified supports. Additionally, the Centers for Medicare & Medicaid Services must implement Medicare policies that increase the identification and response to patients' Alzheimer's disease risk factors and incentivize providers to utilize high-quality cognitive impairment diagnosis practices.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2022 · fourth_quarter · Health Issues
The Concentrating on High-Value Alzheimers Needs to Get to an End Act of 2021 (CHANGE Act) HR 3354/S 1692; Alzheimer's appropriation's at NIH and CDC and HHS.
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies
Client expense: $43,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
The Concentrating on High-Value Alzheimers Needs to Get to an End Act of 2021 (CHANGE Act) HR 3354/S 1692; Alzheimer's appropriation's at NIH and CDC and HHS; The NAPA Reauthorization Act, S. 4203.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
Increasing access to mental health and substance use treatment; Mental Health Parity implementation; S. 1692/H.R. 3753 - Parity Implementation Assistance Act; H.R. 1384/S. 445 - Mainstreaming Addiction and Treatment Act; S. 4306 - Improving Access to Behavioral Health Integration Act; S. 2938 - Bipartisan Safer Communities Act; H.R. 5218 - Collaborate in an Orderly and Cohesive Manner Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act S. 1125/H.R. 2517, recommends that the Center for Medicare and Medicaid Innovation (CMMI) test the effect of different dementia care management model and reimbursement strategies
Client expense: $45,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
The Concentrating on High-Value Alzheimers Needs to Get to an End Act of 2021 (CHANGE Act) HR 3354/S 1692; Alzheimer's appropriation's at NIH and CDC and HHS; The NAPA Reauthorization Act, S. 4203.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
The Concentrating on High-Value Alzheimers Needs to Get to an End Act of 2021 (CHANGE Act) HR 3354/S 1692; Alzheimer's appropriation's at NIH and CDC; Alzheimer's prevention letter.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act
Client expense: $45,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Health Issues
S. 289/ H.R. 869: Research Investment to Spark the Economy Act of 2021 S. 610/ H.R. 1667: Lorna Breen Health Care Provider Protection Act S. 834/ H.R. 2256: Resident Physician Shortage Reduction Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 S. 1024/H.R. 2255: Healthcare Workforce Resilience Act S. 1548/H.R. 3085: Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S. 1810/H.R. 3541: Conrad State 30 and Physician Access Reauthorization Act H.R. 2754: COVID-19 Long Haulers Act H.R. 4122: Resident Education Deferred Interest Act of 2021 H.R. 5435: Bringing Regulatory Advances into Neuroscience (BRAIN) Act S.1692/H.R.3354: Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act H.R. 5376: Build Back Better Act; sections 139001-139003, 139101, 139102, 139201, 139202, 31060, 137402, 137405, 30601, 30602, 137301, and 30801 H.R. 5657: Medical Marijuana Research Act Supporting vaccine requirements for health care workers. Urging reforms to proposed surprise billing regulations to align with congressional intent for payment disputes. Support for creating a Neuroscience Center of Excellence at FDA. Support for eliminating the prohibition on national unique patient identifier. Supporting policies to address the COVID-19 public health emergency, including maintaining telemedicine coverage and ensuring access to affordable health coverage and medications. Support for funding the CDC National Neurological Conditions Surveillance System. Medical research funding related to fetal tissue, AHRQ, Congressionally Directed Medical Research Programs at the Department of Defense, and the NIH including the BRAIN Initiative. Support for funding for the Pediatric Subspecialty Loan Repayment Program.
Client expense: $140,000 · Firm income: Not reported
2021 · fourth_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act
Client expense: $45,000 · Firm income: Not reported
Government targets: Administration on Aging, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2021 · fourth_quarter · Health Issues
The Concentrating on High-Value Alzheimers Needs to Get to an End Act of 2021 (CHANGE Act) HR 3354/S 1692; Alzheimer's appropriation's at NIH and CDC; Alzheimer's prevention letter.
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Health Issues
S. 289/ H.R. 869: Research Investment to Spark the Economy Act of 2021 S. 610/ H.R. 1667: Lorna Breen Health Care Provider Protection Act S. 834/ H.R. 2256: Resident Physician Shortage Reduction Act S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021 S. 1024/H.R. 2255: Healthcare Workforce Resilience Act S. 1548/H.R. 3085: Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S. 1810/H.R. 3541: Conrad State 30 and Physician Access Reauthorization Act H.R. 2754: COVID-19 Long Haulers Act H.R. 4122: Resident Education Deferred Interest Act of 2021 H.R. 5435: Bringing Regulatory Advances into Neuroscience (BRAIN) Act S. 1692/H.R.3354: Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act Support for creating a Neuroscience Center of Excellence at FDA. Support for eliminating the prohibition on national unique patient identifier. Supporting policies to address the COVID-19 public health emergency, including maintaining telemedicine coverage and ensuring access to affordable health coverage and medications. Support for funding the CDC National Neurological Conditions Surveillance System. Medical research funding related to fetal tissue, AHRQ, Congressionally Directed Medical Research Programs at the Department of Defense, and the NIH including the BRAIN Initiative. Support for funding for the Pediatric Subspecialty Loan Repayment Program.
Client expense: $200,000 · Firm income: Not reported
2021 · third_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act
Client expense: $45,000 · Firm income: Not reported
Government targets: Administration on Aging, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2021 · second_quarter · Medical/Disease Research/Clinical Labs
General education about improving research and public health programs to address Alzheimer's; early screenings for cognitive impairment. S. 1692 and H.R. 3354.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Medicare/Medicaid
General education about improving research and public health programs to address Alzheimer's. S. 1692 and H.R. 3354.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Health Issues
General education about improving research and public health programs to address Alzheimer's; early screenings for cognitive impairment. S. 1692 and H.R. 3354.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Medicare/Medicaid
H.R. 2517/S. 1125: A bill to recommend that the Center for Medicare and Medicaid Innovation test the effect of a dementia care management model H.R.3085/S.1548, the Equity in Neuroscience and Alzheimers Clinical Trials (ENACT) Act S.1692/H.R.3354, the Concentrating on High-Value Alzheimers Needs to Get to an End (CHANGE) Act
Client expense: $45,000 · Firm income: Not reported
Government targets: Administration on Aging, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
| Republican |
| MS |
| Debbie Stabenow | Democratic | MI |
| Gary C. Peters | Democratic | MI |
| Jeanne Shaheen | Democratic | NH |
| John Hoeven | Republican | ND |
| Jon Tester | Democratic | MT |
| Kyrsten Sinema | Independent | AZ |
| Richard Blumenthal | Democratic | CT |
| Robert Menendez | Democratic | NJ |
| Robert P. Casey, Jr. | Democratic | PA |
| Roger F. Wicker | Republican | MS |
| Thom Tillis | Republican | NC |
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE